Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1 study found for:    21457066 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Completed
Has Results
Effect of Insulin Glulisine Compared to Insulin Aspart and Insulin Lispro When Administered by Continuous Subcutaneous Insulin Infusion (CSII) on Specific Pump Parameters in Patient With Type 1 Diabetes Mellitus
Condition: Diabetes Mellitus, Type 1
Interventions: Drug: Insulin glulisine;   Drug: Insulin lispro;   Drug: Insulin aspart

Indicates status has not been verified in more than two years